-
Tytuł:
-
Effect of exercise on tumor markers - Is exercise anti-tumorigenic in humans?: A scoping review of preliminary clinical investigations.
-
Autorzy:
-
Kang DW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Barnes O; Green Templeton College, University of Oxford, Oxford, USA.
Vander Heiden MG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Koch Institute for Integrative Cancer Research and the Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Dieli-Conwright CM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: ChristinaM_.
-
Źródło:
-
Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2022 Oct; Vol. 178, pp. 103779. Date of Electronic Publication: 2022 Aug 05.
-
Typ publikacji:
-
Journal Article; Review
-
Język:
-
English
-
Imprint Name(s):
-
Publication: <2005->: Amsterdam : Elsevier Scientific Publishers
Original Publication: Boca Raton, Fla. : CRC Press, 1983-
-
MeSH Terms:
-
Biomarkers, Tumor*
Breast Neoplasms*/diagnosis
Breast Neoplasms*/therapy
Carcinoembryonic Antigen ; Carcinogenesis ; Humans ; Ki-67 Antigen ; Male ; Prostate-Specific Antigen
-
Contributed Indexing:
-
Keywords: Cancer progression; Clinical trials; Exercise; Translational trials; Tumor markers
-
Substance Nomenclature:
-
0 (Biomarkers, Tumor)
0 (Carcinoembryonic Antigen)
0 (Ki-67 Antigen)
EC 3.4.21.77 (Prostate-Specific Antigen)
-
Entry Date(s):
-
Date Created: 20220808 Date Completed: 20220920 Latest Revision: 20220920
-
Update Code:
-
20240104
-
DOI:
-
10.1016/j.critrevonc.2022.103779
-
PMID:
-
35940512
-
It has been increasingly conceptualized that exercise may be able to suppress cancer progression itself based on the preclinical evidence suggesting various mechanisms. The challenges exist in investigating the effects of exercise on tumor progression in human settings. Circulating or tissue-driven tumor markers can be a useful and cost-effective tool in monitoring the progression of some cancers. This scoping review summarized the current evidence on the use of tumor markers in clinical exercise oncology trials. A total of 14 studies were identified, and tumor markers included prostate-specific antigen for prostate cancer, carcinoembryonic antigen and circulating tumor cells for colorectal cancer, and Ki-67 for breast cancer. Treatment settings and exercise prescriptions were highly heterogeneous, while most studies did not find significant exercise-mediated effects on tumor markers. Nevertheless, we provide an insight into the utility and considerations in using tumor markers in clinical exercise oncology research.
Competing Interests: Declaration of Competing Interest All authors declare no conflict of interest.
(Copyright © 2022 Elsevier B.V. All rights reserved.)
